ISSN:0268-4705    

出版商:OVID    

年代:2001

数据来源: OVID

摘要:

Right Ventricular Dysplasia constitutes a genetic cardiomyopathy characterized by fibrous-adipose substitution of the right and rarely of the left ventricular myocardium. This disorder is associated with ventricular arrhythmias ranging from frequent ventricular ectopic beats, nonsustained and sustained ventricular tachycardia of left bundle branch morphology and sudden death. Therefore, the syndrome has been labelled Arrhythmogenic RVD Cardiomyopathy.Diagnostic criteria, preliminary genetic data, and clinical manifestations are summarized and critical addressed, using data from the literature and from our own experience. The most important aspects of the ECG in this syndrome are reviewed and stressed with particular attention to initial versus advanced clinical subsets. The typical anatomical abnormalities and biopsy or pathology material are presented.

ISSN:0268-4705    

出版商:OVID    

年代:2001

数据来源: OVID

摘要:

Intravenous antiarrhythmic drugs can be used as diagnostic tools; for example, adenosine can be used to reveal the underlying rhythm in narrow QRS tachycardia. Newer class III antiarrhythmic agents, like ibutilide and dofetilide, are effective at the conversion of acute atrial fibrillation; however, electrical cardioversion is still the most effective method for restoration of sinus rhythm in persistent atrial fibrillation. Lidocaine and bretylium in the treatment and prevention of ventricular tachyarrhythmia are de-emphasized because of inefficacy, safety concerns (lidocaine), or shortage of drug (bretylium). Procainamide is effective for stable ventricular tachycardia, and amiodarone is effective in the treatment of shock-refractory ventricular fibrillation. Adrenergic blockade is likely important in the management of tachyarrhythmias, particularly in electrical storm, but more data will be necessary to establish its role.

ISSN:0268-4705    

出版商:OVID    

年代:2001

数据来源: OVID

摘要:

Formulation substitution using generic preparations for innovator products is becoming increasingly prevalent in the name of cost containment. So long as generic substitutes are truly clinically equivalent to the innovator compounds, patient harm should not ensue. However, for drugs with a narrow therapeutic index, serious concerns about generic equivalence are beginning to arise, particularly with neurologic, immunosuppressive, anticoagulant, and antiarrhythmic drugs. This article reviews the guidelines used to approve a generic compound and their limitations and provides case-based information as to the adverse clinical consequences—arrhythmia recurrence, proarrhythmia, and death—that have now been reported in association with generic substitution of antiarrhythmic compounds. Additionally, guidelines for allowance or avoidance of antiarrhythmic drug formulation substitution are suggested.

ISSN:0268-4705    

出版商:OVID    

年代:2001

数据来源: OVID

摘要:

Life-threatening ventricular arrhythmias in the athlete nearly always occur in the presence of structural heart disease. In the last few years, 2 new causes of life-threatening arrhythmias have been described in patients with normal hearts—that of the Brugada syndrome and that ofcommotio cordis. Non–life-threatening premature ventricular beats and even nonsustained ventricular tachycardia are not rare, and although usually benign, can be secondary to cardiomyopathies. Athletes with symptoms of syncope, especially if exertional, warrant a complete evaluation. The treatment of athletes and other individuals with life-threatening ventricular arrhythmias has been revolutionized by the implantable cardioverter defibrillator, a device that affords excellent protection from sudden death. Defining those athletes who would benefit from the implantable defibrillator is not always clear. Furthermore, participation in competitive athletics for athletes with life-threatening arrhythmias or structural heart disease known to put the athlete at risk for life-threatening arrhythmias is usually prohibited.

ISSN:0268-4705    

出版商:OVID    

年代:2001

数据来源: OVID

摘要:

During pregnancy a number of rhythm disturbances can occur in both the mother and fetus; these may range from benign ectopy to life-threatening arrhythmias. With a clear understanding of the maternal hemodynamic changes associated with pregnancy, and the appropriate antiarrhythmic therapies available, almost all such cases can be treated successfully. Although no drug is completely safe, most are well tolerated and can be given with relatively low risk. Drug therapy should be avoided during the first trimester of pregnancy if possible and drugs with the longest record of safety should be used as first-line therapy. Conservative therapies should be used when appropriate. Several drug options exist for most maternal and fetal arrhythmias.

ISSN:0268-4705    

出版商:OVID    

年代:2001

数据来源: OVID

摘要:

Atrial fibrillation is a common tachyarrhythmia encountered in clinical practice. Management has become increasingly complex as the therapeutic options have multiplied. Two basic strategies are available: rhythm control with or without pharmacologic manipulation, and rate control with anticoagulation. To date, no randomized controlled trial that compares the two strategies has been completed, although the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) trial is underway. This review outlines the rationale for each of the two basic treatment strategies, providing an overview of the advantages and disadvantages of each. Included are clinical criteria used in selecting the appropriate treatment plan.

ISSN:0268-4705    

出版商:OVID    

年代:2001

数据来源: OVID

摘要:

External cardioversion is a technique used electively or emergently to terminate arrhythmias such as atrial fibrillation, ventricular tachycardia, and ventricular fibrillation. There have been several advances made to modern defibrillators, including an improvement in the efficacy of the delivered shock. Biphasic shock waveforms have been shown to be superior to monophasic shocks and these are being incorporated into modern units. This paper reviews several reports on biphasic defibrillation. In addition, initiatives to make defibrillators more accessible are also being tested. Although not a technological advance, this initiative may significantly improve the survival of victims of out of hospital cardiac arrests.

ISSN:0268-4705    

出版商:OVID    

年代:2001

数据来源: OVID

摘要:

Recent data have emerged to help guide the use of implantable pacemakers and implantable defibrillators in patients who have hypertrophic cardiomyopathy (HCM). Controlled studies of the use of dual chamber pacemakers to treat outflow tract obstruction in HCM have shown little benefit, and have raised the possibility that earlier favorable reports were demonstrating an element of placebo effect. In particular, there is no recent support for earlier claims of regression of ventricular hypertrophy from chronic dual chamber pacing. Several reports have added to our understanding of the risk factors for sudden death in HCM. A normal blood pressure response to exercise appears to identify a subset of patients at low risk for sudden death. In a recent study of a large number of HCM patients, the risk of sudden death was found to be directly proportional to the extent of left ventricular hypertrophy. There is accumulating evidence that the implantable defibrillator is highly effective in terminating malignant ventricular arrhythmias in HCM patients, and HCM patients thought to be at significant risk for sudden death should be offered defibrillator implantation.

ISSN:0268-4705    

出版商:OVID    

年代:2001

数据来源: OVID

摘要:

The rate of implantation of pacemakers and implantable cardioverter-defibrillators (ICDs) is ever-increasing. The relative ease of device implantation utilizing a relatively simple, expeditious, percutaneous approach, without the requirement for general anesthesia or long recuperation times, has fueled enthusiasm for implantation. However, the complication risk is ever-present and forms the subject of this pragmatic review, which is limited to the management of only the surgical complications of device implantation. The management of surgical complications related to the implantation of pacemakers and ICDs should include (1) awareness of potential complications, (2) a meticulous approach to the implantation procedure to avoid complications, (3) approach to diagnosis and (4) specific therapy. With a clear understanding of the accepted implant indications and potential complications, and a meticulous approach to the implant and post implant follow up, the incidence of complications can be minimized.

ISSN:0268-4705    

出版商:OVID    

年代:2001

数据来源: OVID